Compare EVH & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVH | VSTM |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.0M | 731.8M |
| IPO Year | 2015 | 2011 |
| Metric | EVH | VSTM |
|---|---|---|
| Price | $3.39 | $7.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $5.75 | ★ $14.67 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $907,957,000.00 | $30,914,000.00 |
| Revenue This Year | $40.46 | $276.56 |
| Revenue Next Year | $25.06 | $55.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $2.10 | $3.43 |
| 52 Week High | $8.46 | $10.82 |
| Indicator | EVH | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 58.37 |
| Support Level | $2.53 | $7.20 |
| Resistance Level | $3.68 | $8.69 |
| Average True Range (ATR) | 0.18 | 0.41 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 3.12 | 55.59 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.